Skip to main content
Fig. 7 | Journal of Translational Medicine

Fig. 7

From: Beneficial impact of epigallocatechingallate on LDL-C through PCSK9/LDLR pathway by blocking HNF1α and activating FoxO3a

Fig. 7

Schematic summary of hypothetic mechanism of EGCG regulates LDL-C through inhibiting PCSK9. EGCG suppresses PCSK9 production by promoting nuclear FoxO3a, and reducing nuclear HNF1α, resulting in up-regulated LDLR expression and LDL uptake in hepatocytes. Thereby inhibiting liver and circulating PCSK9 levels, and ultimately lowering LDL-C levels

Back to article page